Skip to main content
SpringerLink
Log in

In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria

  • Published:
European Journal of Clinical Microbiology Aims and scope Submit manuscript

Abstract

The inhibitory and bactericidal activity of N-formimidoyl-thienamycin in vitro against 131 clinical isolates selected for their gentamicin resistance was compared with that of cefotaxime and moxalactam. All strains were inhibited by N-formimidoyl-thienamycin concentrations within a range of 0.12–4 mg/l. N-formimidoyl-thienamycin was less active than cefotaxime and moxalactam againstEscherichia coli andKlebsiella spp., and more active than all other antibiotics tested againstSerratia spp.,Enterobacter cloacae, Pseudomonas aeruginosa andAcinetobacter spp. In contrast to the other antibiotics N-formimidoyl-thienamycin showed a narrow margin of difference between minimal inhibitory and minimal bactericidal concentrations. N-formimidoyl-thienamycin is a promising antibiotic for the treatment of hospital infections with multi-resistant organisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wildonger, K. J., Leanza, W. J., Miller, T. W., Christensen, B. G.: N-acetimidoyl and N-formimidoyl-thienamycin, chemically stable, broad spectrum derivatives. 11th International Congress of Chemotherapy/19th Interscience Conference of Antimicrobial Agents and Chemotherapy, Boston 1979, Abstract 232.

  2. Tutlane, V. A., McCloskey, R. V., Trent, J. A.: In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime, and cefoperazone. Antimicrobial Agents and Chemotherapy 1981, 20: 140–143.

    PubMed  Google Scholar 

  3. Verbist, L., Verhaegen, J.: In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime. Antimicrobial Agents and Chemotherapy 1981, 19: 402–406.

    PubMed  Google Scholar 

  4. Wise, R., Andrews, J. M., Patel, N.: N-formimidoy-lthienamycin a novelβ-lactam: an in-vitro comparison with otherβ-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1981, 7: 521–529.

    PubMed  Google Scholar 

  5. Richmond, M. H.: The semi-synthetic thienamycin derivative MKO787 and its properties with respect to a range ofβ-lactamases from clinically relevant bacterial species. Journal of Antimicrobial Chemotherapy 1981, 7: 279–285.

    PubMed  Google Scholar 

  6. Toda, M., Sato, K., Nakazawa, H., Inoue, M., Mitsuhashi, S.: Effect of N-formimidoyl thienamycin (MKO787) onβ-lactamases and activity againstβ-lactamase-producting strains. Antimicrobial Agents and Chemotherapy 1980, 18: 837–838.

    PubMed  Google Scholar 

  7. Smith, S., May, R. S.: N-formimidoyl thienamycin (MKO787): in vitro study. Antimicrobial Agents and Chemotherapy 1981, 19: 201–204.

    PubMed  Google Scholar 

  8. Hanslo, D., King, A., Shannon, K., Warren, Ch., Phillips, I.: N-formimidoyl thienamycin (MKO787): in-vitro antibacterial activity and susceptibility toβ-lactamases compared with that of cefotaxime, moxalactam and otherβ-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1981, 7: 607–617.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Microbiology, Medical Faculty, Technical University, Goethestr. 27-29, 5100, Aachen, FRG

    Zs. Pusztai-Markos & F. Pranada

Authors
  1. Zs. Pusztai-Markos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Pranada
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pusztai-Markos, Z., Pranada, F. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria. Eur. J, Clin. Microbiol. 1, 49–51 (1982). https://doi.org/10.1007/BF02014140

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02014140

Keywords

Search

Navigation